Abstract: There is provided a method for the manufacture of a cream cheese, the method comprising: (i) providing cheese curds, (ii) providing a whey protein solution comprising ideal whey, (iii) subjecting the whey protein solution to a cavitation treatment sufficient to heat the whey protein solution to a temperature of at least 70° C. to provide a heat-treated whey protein solution, (iv) mixing the cheese curds and the heat-treated whey protein solution to form a mixture, and (v) subjecting the mixture to a texture-building heat-treatment to form the cream cheese.

Abstract: A tissue construct comprising includes a self-assembled, scaffold-free, high-density cell aggregate. The cell aggregate includes a plurality of cells and a plurality of biocompatible and biodegradable nanoparticles and/or microparticles that are incorporated within the cell aggregate. The nanoparticles and/or microparticles act as a bulking agent within the cell aggregate to increase the cell aggregate size and/or thickness and improve the mechanical properties of the cell aggregate allowing the cell aggregate to be readily manipulated and formed into tissue constructs with defined architectures.

Abstract: A tissue construct comprising includes a self-assembled, scaffold-free, high-density cell aggregate. The cell aggregate includes a plurality of cells and a plurality of biocompatible and degradable nanoparticles and/or microparticles that are incorporated within the cell aggregate. The nanoparticles and/or microparticles act as a bulking agent and/or provide bioactive agents or signals within the cell aggregate to increase the cell aggregate size and/or thickness and improve the mechanical properties of the cell aggregate and/or regulate cell function within the aggregate allowing the cell aggregate to be readily manipulated and formed into tissue constructs with defined architectures and potential tissue specific functionality.

Abstract: Compositions consisting essentially of phenylephrine tannate, pyrilamine tannate, and guaifenesin which are effective when administered orally for the symptomatic relief of cough and nasal congestion associated with respiratory tract conditions such as the common cold, bronchial asthma, acute and chronic bronchitis are disclosed.

Abstract: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g.

Abstract: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g.